ADMA Biologics

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ADMA Biologics reports robust Q4 results and outlines growth strategies

ADMA Biologics demonstrated strong financial performance and strategic progress in Q4 2022, positioning the company for growth.
The company's focus on operational excellence, product performance, and market acceptance underpins its growth strategy.
Challenges in achieving profitability and market expansion are being addressed through strategic initiatives and operational enhancements.
Opportunities in label expansions, plasma donor targeting, and manufacturing scale-up offer avenues for sustained growth and market differentiation.

ADMA Biologics reports record revenue growth and profitability in Q1

ADMA Biologics demonstrated strong financial performance in Q1 2023, with notable revenue growth and achieving adjusted EBITDA profitability for the first time.
While facing regulatory and operational challenges, the company is strategically positioned for growth, focusing on immune globulin products and patient outcomes.
Management's commitment to innovation, cost efficiencies, and market expansion underscores ADMA's dedication to driving revenue growth and achieving profitability.

ADMA Biologics reports robust Q2 earnings and growth outlook

ADMA Biologics delivered strong financial results, raised revenue guidance, and showcased operational efficiency, positioning the company for sustained growth and market leadership.
The success of ASCENIV and the company's focus on plasma collection underscore ADMA's commitment to patient care, innovation, and social responsibility in the biologics sector.
While facing challenges in a competitive landscape, ADMA has opportunities to expand market reach, increase awareness, and solidify its position as a unique player in the industry.
By balancing financial objectives with social impact goals and emphasizing market differentiation, ADMA can navigate challenges and leverage opportunities for long-term success and stakeholder value.

ADMA Biologics achieves profitability in Q3, poised for growth

ADMA Biologics delivered a strong performance in Q3 2023, achieving profitability for the first time and demonstrating robust revenue growth.
The company's focus on ASCENIV, gross margin improvement, and revenue guidance raise optimism for future prospects and market positioning.
While facing challenges in debt refinancing and patient activation, ADMA Biologics is well-positioned to capitalize on opportunities in product enhancement and market expansion.
Overall, ADMA Biologics' strategic initiatives and financial performance in Q3 indicate a positive trajectory for growth and profitability in the biologics market.

ADMA Biologics achieves positive earnings, focuses on innovation and growth

ADMA Biologics reported a strong financial performance in Q4 2023, achieving positive adjusted net income and cash flow. The company emphasized innovation, growth strategies, and operational efficiencies to drive future success.
While facing challenges in managing profitability and debt, ADMA Biologics is focused on maintaining a strong gross margin profile and developing products targeting specific infectious diseases. The company's commitment to shareholder returns and revenue growth presents opportunities for sustained success.
Overall, ADMA Biologics showcased resilience and strategic planning during the earnings call, with a clear focus on financial stability, innovation, and maximizing shareholder value. The company's positive outlook and growth initiatives position it well for future growth and market competitiveness.

ADMA Biologics reports robust Q1 earnings, eyes sustained growth

ADMA Biologics delivered strong financial performance in Q1 2024, showcasing revenue growth, profitability, and upwardly revised guidance for 2024 and 2025, underlining their growth potential.
The company's focus on innovation, efficiency, and niche markets, along with confidence in long-term growth initiatives, positions them well for sustained value creation and revenue growth beyond 2025.
While facing challenges in operational efficiency, market penetration, and post-2025 revenue growth, ADMA Biologics remains optimistic about growth opportunities and revenue expansion in the coming years.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, NY / ACCESSWIRE / October 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ADMA Biologics, Inc. ("ADMA Biologics, Inc.") (NASDAQ:ADMA) concerning possible violations of federal securities laws. On October 9, 2024, ADMA Biologics disclosed the surprise resignation of its independent outside auditor CohnReznick LLP.

Lost Money on ADMA Biologics, Inc. (ADMA)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

SAN DIEGO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether ADMA Biologics, Inc. (NASDAQ: ADMA) or any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.

Johnson Fistel Begins Investigation into ADMA Biologics, Inc. Following a Significant Drop in the Company's Stock

NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc.

ADMA FRAUD ALERT: BFA Law is Investigating ADMA Biologics, Inc. for Securities Fraud after Stock Drops 20%; Investors with Losses are Urged to Contact the Firm (Nasdaq:ADMA)

Atour Lifestyle Holdings Ltd

Corcept Therapeutics

360 Finance Inc - ADR

Vertiv Holdings Co

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are ATAT, VRT, CORT, QFIN, ADMA.

5 Stocks With Recent Price Strength Amid October Volatility

Investors can contact the law firm at no cost to learn more about recovering their losses

ADMA Biologics, Inc. Investors: Company Investigated by the Portnoy Law Firm

NEW YORK, NY / ACCESSWIRE / October 10, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc.

ADMA STOCK DROP ALERT: ADMA Biologics, Inc. Stock Drops over 20%; BFA Law Initiates Securities Fraud Investigation and Urges Investors with Losses to Contact the Firm (Nasdaq:ADMA)

Block & Leviton is investigating ADMA Biologics for potential securities law violations. Investors who have lost money in ADMA should contact the firm.

ADMA Biologics Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation

The latest trading day saw Adma Biologics (ADMA) settling at $20.33, representing a -1.91% change from its previous close.

Adma Biologics (ADMA) Stock Dips While Market Gains: Key Facts

Lumen Technologies

Powell Industries

Vistra Energy

If you're like most investors — you assume AI giant Nvidia is the best stock of the year. But 2024's major champ isn't even in the S&P 500.

The Real Best Stock Of The Year Isn't In The S&P 500 Yet

Eagle Bancorp Montana

Talos Energy Inc

Targa Resources

Vertex, Inc.

ADMA, VERX, TRGP, EBMT and TALO have been added to the Zacks Rank #1 (Strong Buy) List on October 7, 2024.

New Strong Buy Stocks for October 7th

In the most recent trading session, Adma Biologics (ADMA) closed at $19.50, indicating a -1.37% shift from the previous trading day.

Adma Biologics (ADMA) Stock Sinks As Market Gains: Here's Why

Here is how Adma Biologics (ADMA) and Assembly Biosciences (ASMB) have performed compared to their sector so far this year.

Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?

ADMA Biologics reported $107.2 million in Q2 2024 revenue, a 78% year-over-year increase, with ASCENIV being the primary growth driver. ASCENIV now contributes over 50% of ADMA's total revenue, with significant market potential in treating refractory immunodeficient patients. ASCENIV's unique formulation and potential market penetration could drive peak annual sales over $1 billion, though technological advancements and existing competition pose risks.

ADMA Biologics: Riding High On ASCENIV's Success

Adma Biologics (ADMA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Adma Biologics (ADMA) Is a Great Choice for 'Trend' Investors, Here's Why

This biopharma stock has gained around 330% so far this year and is near record highs.

Biotech Hangs On To Top Spot On This List, And It Even Outshines Nvidia

ADMA stock surges 76.2% in three months on strong performance and high growth prospects. It recently hit its 52-week high with more room for growth.

ADMA Biologics Stock Soars 76.2% in 3 Months: Right Time to Invest?

RAMSEY, N.J. and BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced it will join the S&P SmallCap 600 index, effective prior to the open of trading on Monday, September 23, 2024. The S&P SmallCap 600 seeks to measure the small-cap segment of the U.S. equity market.

ADMA Biologics Set to Join S&P SmallCap 600 Index

If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Here's Why Momentum in Adma Biologics (ADMA) Should Keep going

After reaching an important support level, Adma Biologics (ADMA) could be a good stock pick from a technical perspective. ADMA surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.

Adma Biologics (ADMA) Recently Broke Out Above the 20-Day Moving Average

Adma Biologics (ADMA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

ADMA Biologics Inc (ADMA) Hit a 52 Week High, Can the Run Continue?

RAMSEY, N.J. and BOCA RATON, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference in New York, NY on September 17, 2024, at 3:05 p.m. ET.

ADMA Biologics to Participate in the 2024 Cantor Global Healthcare Conference

Here is how Adma Biologics (ADMA) and CareDx (CDNA) have performed compared to their sector so far this year.

Is ADMA Biologics (ADMA) Outperforming Other Medical Stocks This Year?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic?

The ADMA Biologics (ADMA) stock surges in a month on impressive second-quarter results. It has recently hit its 52-week high with more room for growth.

News for ADMA Biologics Stock (ADMA)